The life of an Olympia man was extended, and he spent three more years with his family as a participant in drug trials that led to approval by the U.S. Food and Drug Administration of the first chemotherapy regimen for asbestos- related cancer.
Al Todak died Jan. 24, weeks before the FDA approved an Alimta-cisplatin combination to treat malignant pleural mesothelioma, a cancer of the lining of the lungs.
News Source: Olympian | Published: March 30, 2004 |
Read Full Story

